January has been a month of change for Abbott, and a senior medical devices analyst from GlobalData asserts that the company’s latest cardiac diagnostics product represents the first step in a line of new diagnostic products that will act to deliver growth over the next few years.

Fujifilm Medical Systems U.S.A. Inc. shared the benefits of its zero footprint mobile application, Synapse Mobility, with visitors to the 2012 meeting of the Radiological Society of North America (RSNA). The application enables access to Fujifilm’s suite of Synapse products from hand-held devices, in addition to Macintosh- or Windows-based PCs. It was one of several Synapse products and solutions demonstrated at the show.

Amplatzer Amulet St. Jude Medical Left Atrial Appendage Occluders

St. Jude Medical Inc. announced European CE mark approval of its Amplatzer Amulet Left Atrial Appendage Occluder. The Amulet device is used to close the left atrial appendage (LAA) in patients diagnosed with non-valvular atrial fibrillation (AF). According to research, AF leads to an increased risk for stroke. Sealing off the LAA helps prevent the risk of blood clot formation and release, potentially reducing the risk of stroke. The next-generation percutaneous transcatheter device leverages the design and clinical success of the original Amplatzer Cardiac Plugwith additional features allowing treatment of a wider range of appendage anatomies. St. Jude Medical will be showcasing the new Amplatzer Amulet device during the 18th annual Boston AF Symposium at booth 319.

Epiphany has received the “Category Leader” recognition in ECG Management from KLAS for the fourth consecutive year.

Top stories of 2012 in cardiology

To help identify trends and find out what DAIC readers are interested in, the magazine takes note of what they click on when visiting the website. Below are the top 25 stories from 2012, and the top 10 stories read in 2012 that were written in previous years.

An estimated 17 million people throughout the world die annually of cardiovascular diseases, specifically heart attacks or strokes. Time is a critical factor in diagnosing and treating people who may be having a potential heart attack. To aid physicians in detecting heart attacks sooner, Abbott announced CE marking for the Architect Stat High Sensitive Troponin-I Assay.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now